The CXCL8-CXCR1/2 pathways in cancer

被引:498
作者
Liu, Qian [1 ]
Li, Anping [2 ]
Tian, Yijun [1 ]
Wu, Jennifer D. [3 ]
Liu, Yu [4 ]
Li, Tengfei [2 ]
Chen, Yuan [1 ]
Han, Xinwei [2 ]
Wu, Kongming [1 ]
机构
[1] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Oncol, Tongji Med Coll, Wuhan 430030, Peoples R China
[2] Zhengzhou Univ, Dept Intervent Radiol, Affiliated Hosp 1, Zhengzhou 450052, Peoples R China
[3] Med Univ South Carolina, Hollings Canc Ctr, Dept Microbiol & Immunol, Charleston, SC USA
[4] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Geriatr, Tongji Med Coll, Wuhan 430030, Peoples R China
基金
国家高技术研究发展计划(863计划); 中国国家自然科学基金;
关键词
CXCL8; CXCR1; CXCR2; Cancer; Angiogenesis; Metastasis; ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; HUMAN-MALIGNANT MELANOMA; NECROSIS-FACTOR-ALPHA; CELL LUNG-CARCINOMA; BREAST-CANCER; PROSTATE-CANCER; INTERLEUKIN-8; EXPRESSION; TUMOR-GROWTH; IN-VITRO;
D O I
10.1016/j.cytogfr.2016.08.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
070307 [化学生物学]; 071010 [生物化学与分子生物学];
摘要
Persistent infection or chronic inflammation contributes significantly to tumourigenesis and tumour progression. C-X-C motif ligand 8 (CXCL8) is a chemokine that acts as an important multifunctional cytokine to modulate tumour proliferation, invasion and migration in an autocrine or paracrine manner. Studies have suggested that CXCL8 and its cognate receptors, C-X-C chemokine receptor 1 (CXCR1) and C-X-C chemokine receptor 2 (CXCR2), mediate the initiation and development of various cancers including breast cancer, prostate cancer, lung cancer, colorectal carcinoma and melanoma. CXCL8 also integrates with multiple intracellular signalling pathways to produce coordinated effects. Neovascularisation, which provides a basis for fostering tumour growth and metastasis, is now recognised as a critical function of CXCL8 in the tumour microenvironment. In this review, we summarize the biological functions and clinical significance of the CXCL8 signalling axis in cancer. We also propose that CXCL8 may be a potential therapeutic target for cancer treatment. (C) 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
引用
收藏
页码:61 / 71
页数:11
相关论文
共 156 条
[1]
MOLECULAR EVOLUTION OF THE HUMAN INTERLEUKIN-8 RECEPTOR GENE-CLUSTER [J].
AHUJA, SK ;
OZCELIK, T ;
MILATOVITCH, A ;
FRANCKE, U ;
MURPHY, PM .
NATURE GENETICS, 1992, 2 (01) :31-36
[2]
Epithelial-to-Mesenchymal Transition and Autophagy Induction in Breast Carcinoma Promote Escape from T-cell-Mediated Lysis [J].
Akalay, Intissar ;
Janji, Bassam ;
Hasmim, Meriem ;
Noman, Muhammad Zaeem ;
Andre, Fabrice ;
De Cremoux, Patricia ;
Bertheau, Philippe ;
Badoual, Cecile ;
Vielh, Philippe ;
Larsen, Annette K. ;
Sabbah, Michele ;
Tan, Tuan Zea ;
Keira, Joan Herr ;
Hung, Nicole Tsang Ying ;
Thiery, Jean Paul ;
Mami-Chouaib, Fathia ;
Chouaib, Salem .
CANCER RESEARCH, 2013, 73 (08) :2418-2427
[3]
Alfaro C., 2016, CLIN CANC RES
[4]
Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer [J].
Araki, Shinako ;
Omori, Yohei ;
Lyn, Dominic ;
Singh, Rajendra K. ;
Meinbach, David M. ;
Sandman, Yekutiel ;
Lokeshwar, Vinata B. ;
Lokeshwar, Bal L. .
CANCER RESEARCH, 2007, 67 (14) :6854-6862
[5]
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice [J].
Arenberg, DA ;
Kunkel, SL ;
Polverini, PJ ;
Glass, M ;
Burdick, MD ;
Strieter, RM .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (12) :2792-2802
[6]
Armstrong C.W., 2016, ONCOTARGET
[7]
The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors [J].
Azenshtein, E ;
Meshel, T ;
Shina, S ;
Barak, N ;
Keydar, I ;
Ben-Baruch, A .
CANCER LETTERS, 2005, 217 (01) :73-86
[8]
Balasoiu M, 2014, ROM J MORPHOL EMBRYO, V55, P575
[9]
Inflammation and cancer: back to Virchow? [J].
Balkwill, F ;
Mantovani, A .
LANCET, 2001, 357 (9255) :539-545
[10]
Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway [J].
Bendre, MS ;
Margulies, AG ;
Walser, B ;
Akel, NS ;
Bhattacharrya, S ;
Skinner, RA ;
Swain, F ;
Ramani, V ;
Mohammad, KS ;
Wessner, LL ;
Martinez, A ;
Guise, TA ;
Chirgwin, JM ;
Gaddy, D ;
Suva, LJ .
CANCER RESEARCH, 2005, 65 (23) :11001-11009